Author Archives: Gastroenterology Journal
Wild-type human PRSS2 and PRSS1R122H cooperatively initiate spontaneous hereditary pancreatitis in transgenic mice
Should we continue or discontinue inflammatory bowel disease medication in patients with COVID-19?
Postprandial plasma lipidomics reveal specific alteration of hepatic-derived diacylglycerols in non-alcoholic fatty liver disease
Hepatic energy metabolism is a dynamic process modulated by multiple stimuli. In non-alcoholic fatty liver disease (NAFLD), human studies typically focus on the static fasting state. We hypothesized that unique postprandial alterations in hepatic lipid… Continue reading
Disparities persist in inclusion of female, pregnant, lactating, and older individuals in inflammatory bowel disease clinical trials
Protocol standardization of microbiome studies – daunting but necessary
Why is cancer of the small intestine increasing?
Pregnancy-Associated Liver Diseases
The liver disorders unique to pregnancy include hyperemesis gravidarum, intrahepatic cholestasis of pregnancy, acute fatty liver of pregnancy and pre-eclampsia-associated hepatic impairment, specifically hemolysis, elevated liver enzymes, and low plate… Continue reading
Genetic predisposition for Helicobacter pylori infection – the jury is still out!
Precision Medicine in Inflammatory Bowel Diseases: Challenges and Considerations for the path forward
IRAK4 signaling drives resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma
Checkpoint immunotherapy is largely ineffective in pancreatic ductal adenocarcinoma (PDAC). The innate immune NF-κB pathway promotes PDAC cell survival, stromal fibrosis and is driven by IRAK4, but its impact on tumor immunity has not been directly inv… Continue reading